AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...
Hosted on MSN36m
How To Treat IgA Nephropathy (Berger's Disease)
Immunoglobulin A nephropathy (known as IgA nephropathy or Berger's disease) is a rare kidney disease that occurs when the ...
healthday42m
FDA Says Drug Makers Will Stop Producing Fentanyl 'Lollipops'
Controversial fentanyl lollipops and similar products will no longer be made by drug makers, the U.S. Food and Drug A ...
Ainos, Inc.: Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
SAN DIEGO, CA / ACCESSWIRE / September 20, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testi ...
Pharmabiz49m
SciSparc submits IND application to US FDA for phase IIb trial for Tourette syndrome
SciSparc submits IND application to US FDA for phase IIb trial for Tourette syndrome: Tel Aviv, Israel Friday, September 20, 2024, 17:30 Hrs [IST] SciSparc Ltd., a specialty clini ...
Keytruda beaten by Summit’s bispecific in NSCLC
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.